Arcutis Biotherapeutics Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA to expand the indication of Zoryve (roflumilast) ) cream 0.3% for the… read more.
Novo Nordisk presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain…. read more.
NICE (UK): Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: i)… read more.
Travere Therapeutics, Inc., announced that the FDA has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for Filspari (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist for… read more.
Idorsia Ltd announced that its novel dual endothelin receptor antagonist (ERA), Tryvio (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic… read more.
NICE(UK): Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults. Durvalumab with tremelimumab can… read more.
-BioXcel Therapeutics, Inc announced that the SERENITY At-Home Pivotal Phase III trial evaluating the safety of BXCL 501, the Company’s proprietary, sublingual film formulation of dexmedetomidine, as an… read more.
Iterum Therapeutics plc announced the U.S. launch of Orlynvah (sulopenem etzadroxil and probenecid) oral tablets. The FDA had approved Orlynvah for adult women with uncomplicated urinary tract infections… read more.
Gilead Sciences Inc. announced that the European Commission (EC) has granted marketing authorization for Yeytuo (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to… read more.
Ionis Pharmaceuticals,Inc. announced that the FDA has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age… read more.
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
Idorsia announced that The Galien Foundation, a premier global institution dedicated to honoring innovators in life sciences, has nominated Tryvio (aprocitentan) in the category of “Best Pharmaceutical Product”… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
